Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis ; volume:23 ; number:1 ; day:29 ; month:8 ; year:2023 ; pages:1-10 ; date:12.2023
BMC neurology ; 23, Heft 1 (29.8.2023), 1-10, 12.2023
- Urheber
-
Saida, Takahiko
Hao, Qi
Kanda, Michihiro
Tani, Yumiko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-023-03297-1
- URN
-
urn:nbn:de:101:1-2023110711513941049438
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Saida, Takahiko
- Hao, Qi
- Kanda, Michihiro
- Tani, Yumiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Postural Control in Relapsing-Remitting Multiple Sclerosis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Postural Control in Relapsing-Remitting Multiple Sclerosis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Postural Control in Relapsing-Remitting Multiple Sclerosis
Abnormal multisensory integration in relapsing–remitting multiple sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis